| 32.8 0.16 (0.49%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 39.99 | 1-year : | 46.71 |
| Resists | First : | 34.24 | Second : | 39.99 |
| Pivot price | 31.35 |
|||
| Supports | First : | 28.62  |
Second : | 25.15 |
| MAs | MA(5) : | 32.59 |
MA(20) : | 30.81 |
| MA(100) : | 20.97 |
MA(250) : | 0 | |
| MACD | MACD : | 1.8 |
Signal : | 1.9 |
| %K %D | K(14,3) : | 75.7 |
D(3) : | 75.3 |
| RSI | RSI(14): 69.8 |
|||
| 52-week | High : | 34.24 | Low : | 9.22 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AXGN ] has closed below upper band by 21.6%. Bollinger Bands are 10.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 32.97 - 33.1 | 33.1 - 33.22 |
| Low: | 31.67 - 31.83 | 31.83 - 31.97 |
| Close: | 32.52 - 32.78 | 32.78 - 33.01 |
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Wed, 24 Dec 2025
AxoGen (NASDAQ:AXGN) Shares Down 3% - Here's What Happened - MarketBeat
Mon, 22 Dec 2025
Are Investors Undervaluing Axogen, Inc. (NASDAQ:AXGN) By 31%? - Yahoo Finance
Tue, 16 Dec 2025
Axogen (AXGN): Reassessing Valuation After FDA BLA Approval for AVANCE Nerve Allograft - Sahm
Sat, 06 Dec 2025
Axogen (AXGN): Reassessing Valuation After FDA Biologics License Approval for AVANCE - Sahm
Sat, 06 Dec 2025
Axogen (AXGN) Price Target Increased by 18.26% to 34.58 - Nasdaq
Thu, 04 Dec 2025
Why Is AXGN Stock Rising Today? - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 46 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 5.5 (%) |
| Held by Institutions | 92.9 (%) |
| Shares Short | 2,850 (K) |
| Shares Short P.Month | 2,730 (K) |
| EPS | -0.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.61 |
| Profit Margin | -1 % |
| Operating Margin | 3.1 % |
| Return on Assets (ttm) | 1.2 % |
| Return on Equity (ttm) | -2 % |
| Qtrly Rev. Growth | 23.5 % |
| Gross Profit (p.s.) | 3.48 |
| Sales Per Share | 4.65 |
| EBITDA (p.s.) | 0.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 7 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | -656 |
| PEG Ratio | 0 |
| Price to Book value | 12.51 |
| Price to Sales | 7.04 |
| Price to Cash Flow | 232.37 |
| Dividend | 1 |
| Forward Dividend | 0 |
| Dividend Yield | 3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|